Predrag Sikirić has been working on BPC-157 since the 1990s & says excitement over the peptide’s possible therapeutic effects wasn’t unexpected.
Yet, media interest hasn’t translated into funding to help put BPC-157 through the required clinical trials:
www.chemistryworld.com/news/croatia...
Trump administration hopes to approve peptides popular with MAHA wellbeing advocates. How are the researchers at the centre of this coping with sudden media fame?